MicroRNAs and adipocytokines: Promising biomarkers for pharmacological targets in diabetes mellitus and its complications

Biomedicine and Pharmacotherapy

Volumn 93, Issue , 2017, Pages 1326-1336

  Ashoori, Mohamad Reza ^a,b   Rahmati Yamchi, Mohammad ^a   Ostadrahimi, Alireza ^b   Fekri Aval, Sedigheh ^c   Zarghami, Nosratollah ^a,b,c  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adipocytokine; MicroRNA; Obesity; Pharmacological target

Indexed keywords

ADIPOCYTOKINE; BIOLOGICAL MARKER; GLUCOSE; INSULIN; MICRORNA; SMALL UNTRANSLATED RNA;

ADIPOGENESIS; DIABETES MELLITUS; DIABETIC COMPLICATION; DRUG TARGETING; GENE EXPRESSION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; WHITE ADIPOSE TISSUE; GENETICS; GLUCOSE BLOOD LEVEL; METABOLISM;

ADIPOKINES; BIOMARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; GENE EXPRESSION; HUMANS; INSULIN; MICRORNAS; PREDIABETIC STATE;

EID: 85025144062     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2017.07.059     Document Type: Review

References (158)

1. Butchart, A., Mikton, C., Dahlberg, L.L., Krug, E.G., Global status report on violenceprevention 2014. Inj. Prev., 21(3), 2015, 213.
2. Dunmore, S.J., Brown, J.E., The role of adipokines in beta-cell failure of type 2 diabetes. J. Endocrinol. 216:1 (2013), T37–45.
3. Mao, Y., Mohan, R., Zhang, S., Tang, X., MicroRNAs as pharmacological targets in diabetes. Pharmacol. Res. 75 (2013), 37–47.
4. Guay, C., Regazzi, R., Circulating microRNAs as novel biomarkers for diabetes mellitus. Nat. Rev. Endocrinol. 9:9 (2013), 513–521.
5. Alizadeh, E., Akbarzadeh, A., Eslaminejad, M.B., Barzegar, A., Hashemzadeh, S., Nejati-Koshki, K., Zarghami, N., Up regulation of liver-enriched transcription factors HNF4a and HNF6 and liver-specific microRNA (miR-122) by inhibition of let-7b in mesenchymal stem cells. Chem. Biol. Drug Des. 85:3 (2015), 268–279.
6. Aval, S.F., Lotfi, H., Sheervalilou, R., Zarghami, N., Tuning of major signaling networks (TGF-β, Wnt, Notch and Hedgehog) by miRNAs in human stem cells commitment to different lineages: possible clinical application. Biomed. Pharmacother. 91 (2017), 849–860.
7. Hui, E., Xu, A., Bo Yang, H., Lam, K.S., Obesity as the common soil of non-alcoholic fatty liver disease and diabetes: role of adipokines. J. Diabetes Invest. 4:5 (2013), 413–425.
8. Flehmig, G., Scholz, M., Kloting, N., Fasshauer, M., Tonjes, A., Stumvoll, M., Youn, B.S., Bluher, M., Identification of adipokine clusters related to parameters of fat mass, insulin sensitivity and inflammation. PLoS One, 9(6), 2014, e99785.
9. Vijayan, M., Reddy, P.H., Peripheral biomarkers of stroke: focus on circulatory microRNAs. Bba-Mol. Basis Dis. 1862:10 (2016), 1984–1993.
10. Parrinello, C.M., Selvin, E., Beyond HbA1c and glucose: the role of nontraditional glycemic markers in diabetes diagnosis, prognosis, and management. Curr. Diab. Rep., 14(11), 2014, 548.
11. Claesson, R., Ignell, C., Shaat, N., Berntorp, K., HbA1c as a predictor of diabetes after gestational diabetes mellitus. Prim. Care Diabetes 11:1 (2017), 46–51.
12. Lee, J.E., Alternative biomarkers for assessing glycemic control in diabetes: fructosamine, glycated albumin, and 1,5-anhydroglucitol. Ann. Pediatr. Endocrinol. Metabolism 20:2 (2015), 74–78.
13. Association, A.D., Standards of medical care in diabetes—2017 abridged for primary care providers. Clin. Diabetes 35:1 (2017), 5–26.
14. Inzucchi, S.E., Lipska, K.J., Mayo, H., Bailey, C.J., McGuire, D.K., Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA 312:24 (2014), 2668–2675.
15. Handorf, A.M., Sollinger, H.W., Alam, T., Insulin gene therapy for type 1 diabetes mellitus. Exp. Clin. transplant. 13:Suppl. 1 (2015), 37–45.
16. Samandari, N., Mirza, A.H., Nielsen, L.B., Kaur, S., Hougaard, P., Fredheim, S., Mortensen, H.B., Pociot, F., Circulating MicroRNA Levels Predict Residual Beta Cell Function and Glycaemic Control in Children with Type 1 Diabetes Mellitus. 2016.
17. Mohammadian, F., Pilehvar-Soltanahmadi, Y., Mofarrah, M., Dastani-Habashi, M., Zarghami, N., Down regulation of miR-18a, miR-21 and miR-221 genes in gastric cancer cell line by chrysin-loaded PLGA-PEG nanoparticles, Artificial cells, nanomedicine. Artificial Cells Nanomed. Biotechno. 44:8 (2016), 1972–1978.
18. Kaviani, M., Azarpira, N., Karimi, M.H., Al-Abdullah, I., The role of microRNAs in islet beta-cell development. Cell Biol. Int. 40:12 (2016), 1248–1255.
19. Marchand, L., Jalabert, A., Meugnier, E., Van den Hende, K., Fabien, N., Nicolino, M., Madec, A.M., Thivolet, C., Rome, S., MiRNA-375 a sensor of glucotoxicity is altered in the serum of children with newly diagnosed type 1 diabetes. J. Diabetes Res., 2016, 2016, 1869082.
20. Sheervalilou, R., Ansarin, K., Fekri Aval, S., Shirvaliloo, S., Pilehvar-soltanahmadi, Y., Mohammadian, M., Zarghami, N., An Update on Sputum MicroRNAs in Lung Cancer Diagnosis. 2016, Diagnostic cytopathology.
21. Eliasson, L., The small RNA miR-375 − a pancreatic islet abundant miRNA with multiple roles in endocrine beta cell function. Mol. Cell. Endocrinol., 2017.
22. El Ouaamari, A., Baroukh, N., Martens, G.A., Lebrun, P., Pipeleers, D., Van Obberghen, E., miR-375 targets 3′-phosphoinositide–dependent protein kinase-1 and regulates glucose-induced biological responses in pancreatic β-cells. Diabetes 57:10 (2008), 2708–2717.
23. Salunkhe, V.A., Esguerra, J.L., Ofori, J.K., Mollet, I.G., Braun, M., Stoffel, M., Wendt, A., Eliasson, L., Modulation of microRNA-375 expression alters voltage-gated Na(+) channel properties and exocytosis in insulin-secreting cells. Acta Physiol. Oxford, England) 213:4 (2015), 882–892.
24. Erener, S., Mojibian, M., Fox, J.K., Denroche, H.C., Kieffer, T.J., Circulating miR-375 as a biomarker of beta-cell death and diabetes in mice. Endocrinology 154:2 (2013), 603–608.
25. Sun, K., Chang, X., Yin, L., Li, J., Zhou, T., Zhang, C., Chen, X., Expression and DNA methylation status of microRNA-375 in patients with type 2 diabetes mellitus. Mol. Med. Rep. 9:3 (2014), 967–972.
26. Higuchi, C., Nakatsuka, A., Eguchi, J., Teshigawara, S., Kanzaki, M., Katayama, A., Yamaguchi, S., Takahashi, N., Murakami, K., Ogawa, D., Sasaki, S., Makino, H., Wada, J., Identification of circulating miR-101, miR-375 and miR-802 as biomarkers for Type 2 Diabetes. Metabolism 64:4 (2015), 489–497.
27. Latreille, M., Herrmanns, K., Renwick, N., Tuschl, T., Malecki, M.T., McCarthy, M.I., Owen, K.R., Rülicke, T., Stoffel, M., miR-375 gene dosage in pancreatic β-cells: implications for regulation of β-cell mass and biomarker development. J. Mol. Med. (Berlin, Germany), 93(10), 2015, 1159.
28. Nathan, G., Kredo-Russo, S., Geiger, T., Lenz, A., Kaspi, H., Hornstein, E., Efrat, S., MiR-375 promotes redifferentiation of adult human beta cells expanded in vitro. PLoS One, 10(4), 2015, e0122108.
29. Bhatia, P., Raina, S., Chugh, J., Sharma, S., miRNAs: early prognostic biomarkers for Type 2 diabetes mellitus?. Biomarkers Med. 9:10 (2015), 1025–1040.
30. Vienberg, S., Geiger, J., Madsen, S., Dalgaard, L.T., MicroRNAs in metabolism. Acta Physiol. (Oxford, England), 2016, 1–16.
31. Zhou, B., Li, C., Qi, W., Zhang, Y., Zhang, F., Wu, J.X., Hu, Y.N., Wu, D.M., Liu, Y., Yan, T.T., Jing, Q., Liu, M.F., Zhai, Q.W., Downregulation of miR-181a upregulates sirtuin-1 (SIRT1) and improves hepatic insulin sensitivity. Diabetologia 55:7 (2012), 2032–2043.
32. Nakagami, H., The mechanism of white and brown adipocyte differentiation. Diabetes Metabol. J. 37:2 (2013), 85–90.
33. Zhang, H.B., Guan, M.P., Townsend, K.L., Huang, T.L., An, D., Yan, X., Xue, R.D., Schulz, T.J., Winnay, J., Mori, M., Hirshman, M.F., Kristiansen, K., Tsang, J.S., White, A.P., Cypess, A.M., Goodyear, L.J., Tseng, Y.H., MicroRNA-455 regulates brown adipogenesis via a novel HIF1an-AMPK-PGC1 signaling network. EMBO Rep. 16:10 (2015), 1378–1393.
34. Codocedo, J.F., Rios, J.A., Godoy, J.A., Inestrosa, N.C., Are microRNAs the molecular link between metabolic syndrome and Alzheimer's disease?. Mol. Neurobiol. 53:4 (2016), 2320–2338.
35. Willeit, P., Skroblin, P., Kiechl, S., Fernández-Hernando, C., Mayr, M., Liver microRNAs: potential mediators and biomarkers for metabolic and cardiovascular disease?. Eur. Heart J. 37 (2016), 3260–3266.
36. Alizadeh, E., Eslaminejad, M.B., Akbarzadeh, A., Sadeghi, Z., Abasi, M., Herizchi, R., Zarghami, N., Upregulation of miR-122 via trichostatin a treatments in hepatocyte-like cells derived from mesenchymal stem cells. Chem. Biol. Drug Des. 87:2 (2016), 296–305.
37. Li, X.L., MiR-375, a microRNA related to diabetes. Gene 533:1 (2014), 1–4.
38. Chen, H., Lan, H.-Y., Roukos, D.H., Cho, W.C., Application of microRNAs in diabetes mellitus. J. Endocrinol. 222:1 (2014), R1–R10.
39. Niculescu, L.S., Simionescu, N., Sanda, G.M., Carnuta, M.G., Stancu, C.S., Popescu, A.C., Popescu, M.R., Vlad, A., Dimulescu, D.R., Simionescu, M., MiR-486 and miR-92a identified in circulating HDL discriminate between stable and vulnerable coronary artery disease patients. PLoS One, 10(10), 2015, e0140958.
40. Guay, C., Roggli, E., Nesca, V., Jacovetti, C., Regazzi, R., Diabetes mellitus, a microRNA-related disease?. Transl. Res. 157:4 (2011), 253–264.
41. Rome, S., Are extracellular microRNAs involved in type 2 diabetes and related pathologies?. Clin. Biochem. 46:10–11 (2013), 937–945.
42. Guay, C., Regazzi, R., MicroRNAs and the functional beta cell mass: for better or worse. Diabetes Metab. 41:5 (2015), 369–377.
43. Zhu, L., Chen, L., Shi, C.M., Xu, G.F., Xu, L.L., Zhu, L.L., Guo, X.R., Ni, Y., Cui, Y., Ji, C., MiR-335, an adipogenesis-related microRNA, is involved in adipose tissue inflammation. Cell Biochem. Biophys. 68:2 (2014), 283–290.
44. Vatandoost, N., Amini, M., Iraj, B., Momenzadeh, S., Salehi, R., Dysregulated miR-103 and miR-143 expression in peripheral blood mononuclear cells from induced prediabetes and type 2 diabetes rats. Gene 572:1 (2015), 95–100.
45. Zhang, S., Guo, L.J., Zhang, G., Wang, L.L., Hao, S., Gao, B., Jiang, Y., Tian, W.G., Cao, X.E., Luo, D.L., Roles of microRNA-124a and microRNA-30d in breast cancer patients with type 2 diabetes mellitus. Tumor Biol. 37:8 (2016), 11057–11063.
46. Meydan, C., Shenhar-Tsarfaty, S., Soreq, H., MicroRNA regulators of anxiety and metabolic disorders. Trends Mol. Med. 22:9 (2016), 798–812.
47. Holik, A.K., Lieder, B., Kretschy, N., Somoza, M.M., Held, S., Somoza, V., N-E-Carboxymethyllysine increases the expression of miR-103/143 and enhances lipid accumulation in 3T3-L1Cells. J. Cell. Biochem. 117:10 (2016), 2413–2422.
48. Foley, N.H., O'Neill, L.A., miR-107: a Toll-like receptor-regulated miRNA dysregulated in obesity and type II diabetes. J. Leukoc. Biol. 92:3 (2012), 521–527.
49. Chien, H.Y., Lee, T.P., Chen, C.Y., Chiu, Y.H., Lin, Y.C., Lee, L.S., Li, W.C., Circulating microRNA as a diagnostic marker in populations with type 2 diabetes mellitus and diabetic complications. J. Chin. Med. Assoc. 78:4 (2015), 204–211.
50. Zhou, J.Y., Li, L.X., MicroRNAs are key regulators of brown adipogenesis. Bba-Mol. Cell Biol. L 1841:11 (2014), 1590–1595.
51. Tao, C., Huang, S.J., Wang, Y.J., Wei, G., Zhang, Y., Qi, D.S., Wang, Y.F., Li, K., Changes in white and brown adipose tissue microRNA expression in cold-induced mice. Biochem. Bioph. Res. Co 463:3 (2015), 193–199.
52. Mastropasqua, R., Toto, L., Cipollone, F., Santovito, D., Carpineto, P., Mastropasqua, L., Role of microRNAs in the modulation of diabetic retinopathy. Prog. Retin. Eye Res. 43 (2014), 92–107.
53. Figueira, M.F., Monnerat-Cahli, G., Medei, E., Carvalho, A.B., Morales, M.M., Lamas, M.E., da Fonseca, R.N., Souza-Menezes, J., MicroRNAs: potential therapeutic targets in diabetic complications of the cardiovascular and renal systems. Acta Physiol. (Oxford, England) 211:3 (2014), 491–500.
54. Xu, L.L., Shi, C.M., Xu, G.F., Chen, L., Zhu, L.L., Zhu, L., Guo, X.R., Xu, M.Y., Ji, C.B., TNF-alpha, IL-6, and leptin increase the expression of miR-378, an adipogenesis-related microRNA in human adipocytes. Cell Biochem. Biophys. 70:2 (2014), 771–776.
55. Gong, W., Xiao, D., Ming, G., Yin, J., Zhou, H., Liu, Z., Type 2 diabetes mellitus-related genetic polymorphisms in microRNAs and microRNA target sites. J. Diabetes 6:4 (2014), 279–289.
56. Locke, J.M., Xavier, G.D., Dawe, H.R., Rutter, G.A., Harries, L.W., Increased expression of miR-187 in human islets from individuals with type 2 diabetes is associated with reduced glucose-stimulated insulin secretion. Diabetologia 57:1 (2014), 122–128.
57. Berends, L.M., Ozanne, S.E., Early determinants of type-2 diabetes, Best practice & research. Clin. Endocrinol. Metab. 26:5 (2012), 569–580.
58. Tang, X., Tang, G., Ozcan, S., Role of microRNAs in diabetes. Biochim. Biophys. Acta 1779:11 (2008), 697–701.
59. Kameswaran, V., Bramswig, N.C., McKenna, L.B., Penn, M., Schug, J., Hand, N.J., Chen, Y., Choi, I., Vourekas, A., Won, K.J., Liu, C., Vivek, K., Naji, A., Friedman, J.R., Kaestner, K.H., Epigenetic regulation of the DLK1-MEG3 microRNA cluster in human type 2 diabetic islets. Cell Metab. 19:1 (2014), 135–145.
60. Zampetaki, A., Kiechl, S., Drozdov, I., Willeit, P., Mayr, U., Prokopi, M., Mayr, A., Weger, S., Oberhollenzer, F., Bonora, E., Shah, A., Willeit, J., Mayr, M., Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ. Res. 107:6 (2010), 810–817.
61. Warren, C.R., Cowan, C.A., Type 1 diabetes and MicroRNA: it's complicated. Cell Metab. 22:2 (2015), 202–203.
62. Xie, Z., Chang, C., Zhou, Z., Molecular mechanisms in autoimmune type 1 diabetes: a critical review. Clin. Rev. Allergy Immunol. 47:2 (2014), 174–192.
63. Nielsen, L.B., Wang, C., Sorensen, K., Bang-Berthelsen, C.H., Hansen, L., Andersen, M.L.M., Hougaard, P., Juul, A., Zhang, C.Y., Pociot, F., Mortensen, H.B., Circulating levels of MicroRNA from children with newly diagnosed type 1 diabetes and healthy controls: evidence that miR-25 associates to residual beta-cell function and glycaemic control during disease progression. Exp. Diabetes Res., 2012.
64. Sebastiani, G., Spagnuolo, I., Patti, A., Grieco, F., Cataldo, D., Ferretti, E., Tiberti, C., Dotta, F., MicroRNA Expression Fingerprint in Serum of Type 1 Diabetic Patients, Diabetologia. 2012, SPRINGER 233 SPRING, ST, NEW YORK, NY 10013 USA, S48.
65. Salas-Perez, F., Codner, E., Valencia, E., Pizarro, C., Carrasco, E., Perez-Bravo, F., MicroRNAs miR-21a and miR-93 are down regulated in peripheral blood mononuclear cells (PBMCs) from patients with type 1 diabetes. Immunobiology 218:5 (2013), 733–737.
66. Sebastiani, G., Grieco, F.A., Spagnuolo, I., Galleri, L., Cataldo, D., Dotta, F., Increased expression of microRNA miR-326 in type 1 diabetic patients with ongoing islet autoimmunity. Diabetes Metab. Res. Rev. 27:8 (2011), 862–866.
67. Hezova, R., Slaby, O., Faltejskova, P., Mikulkova, Z., Buresova, I., Raja, K.R., Hodek, J., Ovesna, J., Michalek, J., microRNA-342, microRNA-191 and microRNA-510 are differentially expressed in T regulatory cells of type 1 diabetic patients. Cell. Immunol. 260:2 (2010), 70–74.
68. Yang, M.L., Ye, L., Wang, B.K., Gao, J., Liu, R.X., Hong, J., Wang, W.Q., Gu, W.Q., Ning, G., Decreased miR-146 expression in peripheral blood mononuclear cells is correlated with ongoing islet autoimmunity in type 1 diabetes patients. J. Diabetes 7:2 (2015), 158–165.
69. Zampetaki, A., Kiechl, S., Drozdov, I., Willeit, P., Mayr, U., Prokopi, M., Mayr, A., Weger, S., Oberhollenzer, F., Bonora, E., Shah, A., Willeit, J., Mayr, M., Plasma MicroRNA profiling reveals loss of endothelial miR-126 and other MicroRNAs in type 2 diabetes. Circ. Res. 107:6 (2010), U359–U810.
70. Kong, L., Zhu, J., Han, W., Jiang, X., Xu, M., Zhao, Y., Dong, Q., Pang, Z., Guan, Q., Gao, L., Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study. Acta Diabetol. 48:1 (2011), 61–69.
71. Rezk, N.A., Sabbah, N.A., Saad, M.S.S., Role of MicroRNA 126 in screening, diagnosis, and prognosis of diabetic patients in Egypt. IUBMB Life 688:6 (2016), 452–458.
72. Setyowati Karolina, D., Armugam, A., Tavintharan, S., Wong, M.T.K., Chi Lim, S., Fang Sum, C., Jeyaseelan, K., MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus. PLoS One, 6(8), 2011, e22839.
73. Zhao, C., Dong, J., Jiang, T., Shi, Z., Yu, B., Zhu, Y., Chen, D., Xu, J., Huo, R., Dai, J., Early second-trimester serum miRNA profiling predicts gestational diabetes mellitus. PLoS One, 6(8), 2011, e23925.
74. Collares, C.V., Evangelista, A.F., Xavier, D.J., Rassi, D.M., Arns, T., Foss-Freitas, M.C., Foss, M.C., Puthier, D., Sakamoto-Hojo, E.T., Passos, G.A., Donadi, E.A., Identifying common and specific microRNAs expressed in peripheral blood mononuclear cell of type 1, type 2, and gestational diabetes mellitus patients. BMC Res. Notes, 6, 2013, 491.
75. Chou, C.F., Lin, Y.Y., Wang, H.K., Zhu, X.L., Giovarelli, M., Briata, P., Gherzi, R., Garvey, W.T., Chen, C.Y., KSRP ablation enhances brown fat gene program in white adipose tissue through reduced miR-150 expression. Diabetes 63:9 (2014), 2949–2961.
76. Thome, J.G., Mendoza, M.R., heuiche, A.V., La Porta, V.L., Silvello, D., dos Santos, K.G., Andrades, M.E., Clausell, N., Rohde, L.E., Biolo, A., Circulating microRNAs in obese and lean heart failure patients: a case-control study with computational target prediction analysis. Gene 574:1 (2015), 1–10.
77. Li, M.Y., Pan, S.R., Qiu, A.Y., Roles of microRNA-221/222 in type 2 diabetic patients with post-menopausal breast cancer. Genet. Mol. Res., 15(2), 2016.
78. Pek, S.L.T., Sum, C.F., Lin, M.X., Cheng, A.K.S., ong, M.T.K., Lim, S.C., Tavintharan, S., Circulating and visceral adipose miR-100 is down-regulated in patients with obesity and Type 2 diabetes. Mol. Cell. Endocrinol. 427 (2016), 112–123.
79. Fu, X.H., Dong, B.N., Tian, Y., Lefebvre, P., Meng, Z.P., Wang, X.C., Pattou, F., Han, W.D., Wang, X.Q., Lou, F., Jove, R., Staels, B., Moore, D.D., Huang, W.D., MicroRNA-26a regulates insulin sensitivity and metabolism of glucose and lipids. J. Clin. Invest. 125:6 (2015), 2497–2509.
80. Sun, X.H., Lin, J.B., Zhang, Y., Kang, S.N., Belkin, N., Wara, A.K., Icli, B., Hamburg, N.M., Li, D.Z., Feinberg, M.W., MicroRNA-181b improves glucose homeostasis and insulin sensitivity by regulating endothelial function in white adipose tissue. Circ. Res. 118:5 (2016), 810–821.
81. Liu, L.L., Li, Q.F., Xiao, X.Q., Wu, C.D., Gao, R.F., Peng, C.A., Li, D.T., Zhang, W.L., Du, T.T., Wang, Y., Yang, S.M., Zhen, Q.N., Ge, Q., miR-1934, downregulated in obesity, protects against low-grade inflammation in adipocytes. Mol. Cell. Endocrinol. 428(C (2016), 109–117.
82. Karbiener, M., Pisani, D.F., Frontini, A., Oberreiter, L.M., Lang, E., Vegiopoulos, A., Mossenbock, K., Bernhardt, G.A., Mayr, T., Hildner, F., Grillari, J., Ailhaud, G., Herzig, S., Cinti, S., Amri, E.Z., Scheideler, M., MicroRNA-26 family is required for human adipogenesis and drives characteristics of brown adipocytes. Stem Cells 32:6 (2014), 1578–1590.
83. Osipova, J., Fischer, D.-C., Dangwal, S., Volkmann, I., Widera, C., Schwarz, K., Lorenzen, J.M., Schreiver, C., Jacoby, U., Heimhalt, M., Diabetes-associated microRNAs in pediatric patients with type 1 diabetes mellitus: a cross-sectional cohort study. J. Clin. Endocrinol. Metab. 99:9 (2014), E1661–E1665.
84. Zhong, X., Chung, A.C.K., Chen, H.Y., Dong, Y., Meng, X.M., Li, R., Yang, W., Hou, F.F., Lan, H.Y., miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes. Diabetologia 56:3 (2013), 663–674.
85. McClelland, A.D., Herman-Edelstein, M., Komers, R., Jha, J.C., Winbanks, C.E., Hagiwara, S., Gregorevic, P., Kantharidis, P., Cooper, M.E., miR-21 promotes renal fibrosis in diabetic nephropathy by targeting PTEN and SMAD7. Clin. Sci. 129:12 (2015), 1237–1249.
86. Qing, S., Yuan, S., Yun, C., Hui, H., Mao, P., Wen, F., Ding, Y., Liu, Q., Serum miRNA biomarkers serve as a fingerprint for proliferative diabetic retinopathy. Cell. Physiol. Biochem. 34:5 (2014), 1733–1740.
87. Dey, N., Das, F., Mariappan, M.M., Mandal, C.C., Ghosh-Choudhury, N., Kasinath, B.S., Choudhury, G.G., MicroRNA-21 orchestrates high glucose-induced signals to TOR complex 1, resulting in renal cell pathology in diabetes. J. Biol. Chem. 286:29 (2011), 25586–25603.
88. Ruan, Q., Wang, T., Kameswaran, V., Wei, Q., Johnson, D.S., Matschinsky, F., Shi, W., Chen, Y.H., The microRNA-21- PDCD4 axis prevents type 1 diabetes by blocking pancreatic β cell death. Proc. Natl. Acad. Sci. 108:29 (2011), 12030–12035.
89. Lee, D.E., Brown, J.L., Rosa, M.E., Brown, L.A., Perry, R.A., Wiggs, M.P., Nilsson, M.I., Crouse, S.F., Fluckey, J.D., Washington, T.A., Greene, N.P., MicroRNA-16 is downregulated during insulin resistance and controls skeletal muscle protein accretion. J. Cell. Biochem. 117:8 (2016), 1775–1787.
90. Gu, N., You, L.H., Shi, C.M., Yang, L., Pang, L.X., Cui, X.W., Ji, C.B., Zheng, W., Guo, X.R., Expression of miR-199a-3p in human adipocytes is regulated by free fatty acids and adipokines. Mol. Med. Rep. 14:2 (2016), 1180–1186.
91. Jin, M., Wu, Y.T., Wang, J., Chen, J., Huang, Y.T., Rao, J.P., Feng, C., MicroRNA-24 promotes 3T3-L1 adipocyte differentiation by directly targeting the MAPK7 signaling. Biochem. Biophys. Res. Co 474:1 (2016), 76–82.
92. Chen, L., Dai, Y.M., Ji, C.B., Yang, L., Shi, C.M., Xu, G.F., Pang, L.X., Huang, F.Y., Zhang, C.M., Guo, X.R., MiR-146b is a regulator of human visceral preadipocyte proliferation and differentiation and its expression is altered in human obesity. Mol. Cell. Endocrinol. 393:1–2 (2014), 65–74.
93. Zheng, H.L., Dong, X.K., Liu, N., Xia, W.M., Zhou, L.L., Chen, X.J., Yang, Z.Q., Chen, X.D., Regulation and mechanism of mouse miR-130a/b in metabolism-related inflammation. Int. J. Biochem. Cell B 74 (2016), 72–83.
94. Ng, R., Wu, H., Xiao, H., Chen, X., Willenbring, H., Steer, C.J., Song, G.S., Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia. Hepatology 60:2 (2014), 554–564.
95. Marchand, A., Atassi, F., Mougenot, N., Clergue, M., Codoni, V., Berthuin, J., Proust, C., Tregouet, D.A., Hulot, J.S., Lompre, A.M., miR-322 regulates insulin signaling pathway and protects against metabolic syndrome-induced cardiac dysfunction in mice. Bba-Mol. Basis Dis. 1862:4 (2016), 611–621.
96. Xie, X.W., Song, J., Li, G., MiR-21a-5p suppresses bisphenol A-induced pre-adipocyte differentiation by targeting map2k3 through MKK3/p38/MAPK. Biochem. Biophys. Res. Co 473:1 (2016), 140–146.
97. Rojas, L.B., Weigelt, K., de Wit, H., zcan, B., van Oudenaren, A., Sempertegui, F., Sijbrands, E., Grosse, L., van Zonneveld, A.J., Drexhage, H.A., Leenen, P.J.M., Study on inflammation-related genes and microRNAs, with special emphasis on the vascular repair factor HGF and miR-574-3p, in monocytes and serum of patients with T2D. Diabetol. Metab. Syndr., 2016, 8.
98. Zhang, T., Li, L.L., Shang, Q.K., Lv, C.F., Wang, C.Y., Su, B., Circulating miR-126 is a potential biomarker to predict the onset of type 2 diabetes mellitus in susceptible individuals. Biochem. Biophys. Res. Co 463:1–2 (2015), 60–63.
99. Liu, Y., Gao, G.Q., Yang, C., Zhou, K., Shen, B.Z., Liang, H.Y., Jiang, X.F., The role of circulating microRNA-126 (miR-126): a novel biomarker for screening prediabetes and newly diagnosed type 2 diabetes mellitus. Int. J. Mol. Sci. 15:6 (2014), 10567–10577.
100. Liu, H.Y., Jin, M.M., Tian, H., Li, J., Li, N., Yan, S.T., MiR-34a and miR-34c are involved in the pathogenesis of type-2 diabetes by modulating the cell cycle of pancreatic beta-cell. Int. J. Clin. Exp. Pathol. 9:5 (2016), 5340–5345.
101. Raut, S.K., Singh, G.B., Rastogi, B., Saikia, U.N., Mittal, A., Dogra, N., Singh, S., Prasad, R., Khullar, M., miR-30c and miR-181a synergistically modulate p53-p21 pathway in diabetes induced cardiac hypertrophy. Mol. Cell. Biochem. 417:1–2 (2016), 191–203.
102. Yang, W.M., Min, K.H., Lee, W., MiR-1271 upregulated by saturated fatty acid palmitate provokes impaired insulin signaling by repressing INSR and IRS-1 expression in HepG2 cells. Biochem. Biophys. Res. Co 478:4 (2016), 1786–1791.
103. Kato, M., Castro, N.E., Natarajan, R., MicroRNAs: potential mediators and biomarkers of diabetic complications. Free Radic. Biol. MedM 64 (2013), 85–94.
104. Gong, Q., Lu, Z., Huang, Q., Ruan, L., Chen, J., Liang, Y., Wang, H., Yue, Y., Feng, S., Altered microRNAs expression profiling in mice with diabetic neuropathic pain. Biochem. Biophys. Res. Commun. 456:2 (2015), 615–620.
105. Shan, Q., Zheng, G.H., Zhu, A.H., Cao, L., Lu, J., Wu, D.M., Zhang, Z.F., Fan, S.H., Sun, C.H., Hu, B., Zheng, Y.L., Epigenetic modification of miR-10a regulates renal damage by targeting CREB1 in type 2 diabetes mellitus. Toxicol. Appl. Pharm. 306 (2016), 134–143.
106. Deiuliis, J.A., MicroRNAs as regulators of metabolic disease: pathophysiologic significance and emerging role as biomarkers and therapeutics. Int. J. Obes. 40:1 (2005), 8–101 (2016).
107. Mancuso, P., The role of adipokines in chronic inflammation. Immuno. Targets Therapy, 5, 2016, 47.
108. Bluher, M., Adipokines − removing road blocks to obesity and diabetes therapy. Mol. MetabM 3:3 (2014), 230–240.
109. Andrade-Oliveira, V., Camara, N.O., Moraes-Vieira, P.M., Adipokines as drug targets in diabetes and underlying disturbances. J. Diabetes Res., 2015, 2015, 681612.
110. Bluher, M., Clinical relevance of adipokines. Diabetes Metab. J. 36:5 (2012), 317–327.
111. Wynn, T.A., Chawla, A., Pollard, J.W., Macrophage biology in development, homeostasis and disease. Nature 496:7446 (2013), 445–455.
112. Morioka, T., Emoto, M., Yamazaki, Y., Kawano, N., Imamura, S., Numaguchi, R., Urata, H., Motoyama, K., Mori, K., Fukumoto, S., Koyama, H., Shoji, T., Inaba, M., Leptin is associated with vascular endothelial function in overweight patients with type 2 diabetes. Cardiovasc. Diabetol., 13, 2014, 10.
113. Nowak, C., Sundstrom, J., Gustafsson, S., Giedraitis, V., Lind, L., Ingelsson, E., Fall, T., Protein biomarkers for insulin resistance and type 2 diabetes risk in two large community cohorts. Diabetes 65:1 (2016), 276–284.
114. Lieb, D.C., Parson, H.K., Mamikunian, G., Vinik, A.I., Cardiac autonomic imbalance in newly diagnosed and established diabetes is associated with markers of adipose tissue inflammation. Exp. Diabetes Res., 2012, 2012, 878760.
115. Niedowicz, D.M., Reeves, V.L., Platt, T.L., Kohler, K., Beckett, T.L., Powell, D.K., Lee, T.L., Sexton, T.R., Song, E.S., Brewer, L.D., Latimer, C.S., Kraner, S.D., Larson, K.L., Ozcan, S., Norris, C.M., Hersh, L.B., Porter, N.M., Wilcock, D.M., Murphy, M.P., Obesity and diabetes cause cognitive dysfunction in the absence of accelerated beta-amyloid deposition in a novel murine model of mixed or vascular dementia. Acta Neuropathol. Commun., 2, 2014, 64.
116. Mohammadzadeh, G., Zarghami, N., Serum leptin level is reduced in non-obese subjects with type 2 diabetes. Int. J. Endocrinol. Metab., 11(1), 2013, 3.
117. Pham, M.N., Kolb, H., Mandrup-Poulsen, T., Battelino, T., Ludvigsson, J., Pozzilli, P., Roden, M., Schloot, N.C., European, C.P.T., Serum adipokines as biomarkers of beta-cell function in patients with type 1 diabetes: positive association with leptin and resistin and negative association with adiponectin. Diabetes Metab. Res. Rev. 29:2 (2013), 166–170.
118. Neuparth, M.J., Proenca, J.B., Santos-Silva, A., Coimbra, S., Adipokines, oxidized low-density lipoprotein, and C-reactive protein levels in lean, overweight, and obese portuguese patients with type 2 diabetes. ISRN Obes, 2013, 2013, 142097.
119. Davis, S.K., Gebreab, S.Y., Xu, R., Riestra, P., Khan, R.J., Sumner, A.E., Hickson, D., Bidulescu, A., Association of adiponectin with type 2 diabetes and hypertension in African American men and women: the Jackson Heart Study. BMC Cardiovasc. Disord., 15, 2015, 13.
120. Bjornstad, P., Truong, U., Dorosz, J.L., Cree-Green, M., Baumgartner, A., Coe, G., Pyle, L., Regensteiner, J.G., Reusch, J.E., Nadeau, K.J., Cardiopulmonary dysfunction and adiponectin in adolescents with type 2 diabetes. J. Am. Heart Assoc., 5(3), 2016, e002804.
121. Ley, S.H., Harris, S.B., Connelly, P.W., Mamakeesick, M., Gittelsohn, J., Hegele, R.A., Retnakaran, R., Zinman, B., Hanley, A.J., Adipokines and incident type 2 diabetes in an aboriginal canadian [corrected] population: the Sandy lake health and diabetes project. Diabetes Care 31:7 (2008), 1410–1415.
122. Kim, S.Y., Sy, V., Araki, T., Babushkin, N., Huang, D., Tan, D., Liao, E., Liu, G., Wan, S., Poretsky, L., Seto-Young, D., Total adiponectin, but not inflammatory markers C-reactive protein, tumor necrosis factor-alpha, interluekin-6 and monocyte chemoattractant protein-1, correlates with increasing glucose intolerance in pregnant Chinese-Americans. J. Diabetes 6:4 (2014), 360–368.
123. Abell, S.K., De Courten, B., Boyle, J.A., Teede, H.J., Inflammatory and other biomarkers role in pathophysiology and prediction of gestational diabetes mellitus. Int. J. Mol. Sci. 16:6 (2015), 13442–13473.
124. Esteve, E., Recart, W., Fernandez-Real, J., Adipocytokines and insulin resistance. Diabetes Care 32 (2009), S362–S367 (Supplement 2).
125. Halabis, M., Dziedzic, M., Warchulinska, J., Kaznowska-Bystryk, I., Solski, J., Omentin-a new adipokine with many roles to play. Curr. Issues Pharm. Med. Sci. 28:3 (2015), 176–180.
126. Nakatsuka, A., Wada, J., Iseda, I., teshigawara, S., Higashio, K., Murakami, K., Kanzaki, M., Inoue, K., Terami, T., Katayama, A., Hida, K., Eguchi, J., Horiguchi, C.S., Ogawa, D., Matsuki, Y., Hiramatsu, R., Yagita, H., Kakuta, S., Iwakura, Y., Makino, H., Vaspin is an adipokine ameliorating ER stress in obesity as a ligand for cell-surface GRP78/MTJ-1 complex. Diabetes 61 (2012), 2823–2832.
127. Saboori, S., Hosseinzadeh-Attar, M., Hosseini, M., Mirzaei, K., Ahmadivand, Z., The comparison of serum vaspin and visfatin concentrations in obese and normal weight women. Diabetes Metab. Syndr.: Clin. Res. Rev. 9:4 (2015), 320–323.
128. Yan, M., Su, B., Peng, W., Li, L., Li, H., Zhuang, J., Lu, Y., Jian, W., Wei, Y., Li, W., Qu, S., Xu, Y., Association of serum vaspin and adiponectin levels with renal function in patients with or without type 2 diabetes mellitus. J. Diabetes Res., 2014, 2014, 868732.
129. Ning, H., Tao, H., Weng, Z., Zhao, X., Plasma fatty acid-binding protein 4 (FABP4) as a novel biomarker to predict gestational diabetes mellitus. Acta Diabetol. 53:6 (2016), 891–898.
130. Shibata, R., Ohashi, K., Murohara, T., Ouchi, N., The potential of adipokines as therapeutic agents for cardiovascular disease. Cytokine Growth Factor Rev. 25:4 (2014), 483–487.
131. Zhou, Y.H., Deng, L., Zhao, D.D., Chen, L.L., Yao, Z., Guo, X.W., Liu, X., Lv, L.F., Leng, B., Xu, W., Qiao, G.F., Shan, H.L., MicroRNA-503 promotes angiotensin II-induced cardiac fibrosis by targeting Apelin-13. J. Cell. Mol. Med. 20:3 (2016), 495–505.
132. Du, H., Fu, Z., He, G., Wang, Y., Xia, G., Fang, M., Zhang, T., MicroRNA-218 targets adiponectin receptor 2 to regulate adiponectin signaling. Mol. Med. Rep. 11:6 (2015), 4701–4705.
133. Zhang, X.M., Wang, L.H., Su, D.J., Zhu, D., Li, Q.M., Chi, M.H., MicroRNA-29b promotes the adipogenic differentiation of human adipose tissue-derived stromal cells. Obesity 24:5 (2016), 1097–1105.
134. Wen, F.Y., Li, B., Huang, C.Y., Wei, Z.G., Zhou, Y.Y., Liu, J.Y., Zhang, H.W., MiR-34a is involved in the decrease of ATP contents induced by resistin through target on ATP5S in HepG2Cells. Biochem. Genet. 53:11–12 (2015), 301–309.
135. Ge, Q., Gerard, J., Noel, L., Scroyen, I., Brichard, S.M., MicroRNAs regulated by adiponectin as novel targets for controlling adipose tissue inflammation. Endocrinology 153:11 (2012), 5285–5296.
136. Li, Y., Cai, X., Guan, Y., Wang, L., Wang, S., Li, Y., Fu, Y., Gao, X., Su, G., Adiponectin upregulates miR-133a in cardiac hypertrophy through AMPK activation and reduced ERK1/2 phosphorylation. PLoS One, 11(2), 2016, e0148482.
137. Subedi, A., Park, P.H., Autocrine and paracrine modulation of microRNA-155 expression by globular adiponectin in RAW 264.7 macrophages: involvement of MAPK/NF-kappaB pathway. Cytokine 64:3 (2013), 638–641.
138. Zhu, L., Shi, C., Ji, C., Xu, G., Chen, L., Yang, L., Fu, Z., Cui, X., Lu, Y., Guo, X., FFAs and adipokine-mediated regulation of hsa-miR-143 expression in human adipocytes. Mol. Biol. Rep. 40:10 (2013), 5669–5675.
139. Crepin, D., Benomar, Y., Riffault, L., Amine, H., Gertler, A., Taouis, M., The over-expression of miR-200a in the hypothalamus of ob/ob mice is linked to leptin and insulin signaling impairment. Mol. Cell. Endocrinol. 384:1-2 (2014), 1–11.
140. Jiang, X., Yang, L., Pang, L., Chen, L., Guo, X., Ji, C., Shi, C., Ni, Y., Expression of obesityrelated miR1908 in human adipocytes is regulated by adipokines, free fatty acids and hormones. Mol. Med. Rep. 10:2 (2014), 1164–1169.
141. Xu, G., Ji, C., Shi, C., Fu, H., Zhu, L., Zhu, L., Xu, L., Chen, L., Feng, Y., Zhao, Y., Guo, X., Modulation of hsa-miR-26b levels following adipokine stimulation. Mol. Biol. Rep. 40:5 (2013), 3577–3582.
142. Yang, W.H., Tsai, C.H., Fong, Y.C., Huang, Y.L., Wang, S.J., Chang, Y.S., Tang, C.H., Leptin induces oncostatin M production in osteoblasts by downregulating miR-93 through the Akt signaling pathway. Int. J. Mol. Sci. 15:9 (2014), 15778–15790.
143. Ceylan-Isik, A.F., Kandadi, M.R., Xu, X., Hua, Y., Chicco, A.J., Ren, J., Nair, S., Apelin administration ameliorates high fat diet-induced cardiac hypertrophy and contractile dysfunction. J. Mol. Cell. Cardiol. 63 (2013), 4–13.
144. Chou, W.W., Wang, Y.T., Liao, Y.C., Chuang, S.C., Wang, S.N., Juo, S.H., Decreased microRNA-221 is associated with high levels of TNF-alpha in human adipose tissue-derived mesenchymal stem cells from obese woman, Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry. Cell. Physiol. Biochem.: Int. J. Exp. Cell. Physiol. Biochem. 32:1 (2013), 127–137.
145. Tsai, C.H., Tsai, H.C., Huang, H.N., Hung, C.H., Hsu, C.J., Fong, Y.C., Hsu, H.C., Huang, Y.L., Tang, C.H., Resistin promotes tumor metastasis by down-regulation of miR-519d through the AMPK/p38 signaling pathway in human chondrosarcoma cells. Oncotarget 6:1 (2015), 258–270.
146. Rodrigues, K.F., Pietrani, N.T., Bosco, A.A., Sousa, L.P., Ferreira, C.N., Sandrim, V.C., Gomes, K.B., Endocan: a new biomarker associated with inflammation in type 2 diabetes mellitus?. Diabetes Metab. Res. Rev. 31:5 (2015), 479–480.
147. Fjeldborg, K., Christiansen, T., Bennetzen, M., Bennetzen, M., J.M, H., Pedersen, S.B., Richelsen, B., The macrophage-specific serum marker, soluble CD163, is increased in obesity and reduced after dietary-induced weight loss. Obesity (Silver Spring) 21:12 (2013), 2437–2443.
148. Liu, Y., Prentice, K.J., Eversley, J.A., Hu, C., Batchuluun, B., Leavey, K., Hansen, J.B., Wei, D.W., Cox, B., Dai, F.F., Jia, W., Wheeler, M.B., Rapid elevation in CMPF may act as a tipping point in diabetes development. Cell Rep. 14:12 (2016), 2889–2900.
149. Esteghamati, A., Aflatoonian, M., Rad, M.V., Mazaheri, T., Mousavizadeh, M., Nakhjavani, M., Noshad, S., Association of osteoprotegerin with peripheral artery disease in patients with type 2 diabetes. Arch. Cardiovasc. Dis. 108:8–9 (2015), 412–419.
150. Papadopoulou-Marketou, N., Skevaki, C., Kosteria, I., Peppa, M., Chrousos, G.P., Papassotiriou, I., Kanaka-Gantenbein, C., NGAL and cystatin C: two possible early markers of diabetic nephropathy in young patients with type 1 diabetes mellitus: one year follow up. Hormones (Athens, Greece) 14:2 (2015), 232–240.
151. Crane, J.D., Palanivel, R., Mottillo, E.P., Bujak, A.L., Wang, H., Ford, R.J., Collins, A., Blumer, R.M., Fullerton, M.D., Yabut, J.M., Kim, J.J., Ghia, J.E., Inhibiting peripheral serotonin synthesis reduces obesity and metabolic dysfunction by promoting brown adipose tissue thermogenesis. 2015, 166–172 21 (2).
152. Faghihi-Kashani, S., Bonnet, F., Hafezi-Nejad, N., Heidari, B., Aghajani Nargesi, A., Sheikhbahaei, S., Ebadi, M., Esteghamati, A., Fasting hyperinsulinaemia and 2-h glycaemia predict coronary heart disease in patients with type 2 diabetes. Diabetes Metab. 42:1 (2016), 55–61.
153. Tsai, S.F., Su, C.W., Wu, M.J., Chen, C.H., Fu, C.P., Liu, C.S., Hsieh, M., Urinary cyclophilin a as a new marker for diabetic nephropathy: a cross-sectional analysis of diabetes mellitus. Medicine (Baltimore), 94(42), 2015, e1802.
154. Niu, Y., Zhang, W., Yang, Z., Li, X., Wen, J., Wang, S., Zhang, H., Wang, X., Zhou, H., Fang, W., Qin, L., Su, Q., Association of plasma osteoprotegerin levels with the severity of lower extremity arterial disease in patients with type 2 diabetes. BMC Cardiovasc. Disord., 15, 2015, 86.
155. Nicolaidou, V., Koufaris, C., MicroRNA responses to environmental liver carcinogens: biological and clinical significance. Clin. Chim. Acta 445 (2015), 25–33.
156. Marques-Rocha, J.L., Samblas, M., Milagro, F.I., Bressan, J., Martinez, J.A., Marti, A., Noncoding RNAs, cytokines, and inflammation-related diseases. FASEB J. 29:9 (2015), 3595–3611.
157. Flowers, E., Won, G.Y., Fukuoka, Y., MicroRNAs associated with exercise and diet: a systematic review. Physiol. Genomics 47:1 (2015), 1–11.
158. Bork-Jensen, J., Thuesen, A.C.B., Bang-Bertelsen, C.H., Grunnet, L.G., Pociot, F., Beck-Nielsen, H., Ozanne, S.E., Poulsen, P., Vaag, A., Genetic versus non-genetic regulation of miR-103, miR-143 and miR-483-3p expression in adipose tissue and their metabolic implications-a twin study. Genes-Basel 5:3 (2014), 508–517.